CD1E

Across TCGA pan-cancer cohorts, CD1E Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD1E data layer compared with 26 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher CD1E Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD1E expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SARC, UCEC, and LGG are the cancer types where CD1E Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.151	0.614	.001	9	view →
UCEC	DFS	Median	III,IV	0.906	0.530	.041	8	view →
LGG	OS	Median	All	0.202	0.892	<.001	7	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CD1E–SARC (DFS)

Open the SARC breakdown →